US 11,807,642 B2
5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents
Benjamin E. Blass, Eagleville, PA (US); Daniel J. Canney, Ambler, PA (US); and Kevin M. Blattner, Folsom, PA (US)
Assigned to Temple University—Of The Commonwealth System of Higher Education, Philadelphia, PA (US)
Filed by Temple University—Of the Commonwealth System of Higher Education, Philadelphia, PA (US)
Filed on Dec. 3, 2021, as Appl. No. 17/541,682.
Application 17/541,682 is a continuation of application No. 16/496,065, granted, now 11,220,505, previously published as PCT/US2018/022581, filed on Mar. 15, 2018.
Claims priority of provisional application 62/474,280, filed on Mar. 21, 2017.
Prior Publication US 2022/0348581 A1, Nov. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) 13 Claims
 
1. A compound having formula (IVa):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1a and R1b are both ethyl; and
at least 2 of the group R3a, R3b, R3c, R3d, and R3e are hydrogen and 0 to 3 of R3a, R3b, R3c, R3d, and R3e are independently selected from the group consisting of OH, NO2, halogen, CN, C1-6 linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl, C1-6 linear alkoxy, C3-7 branched alkoxy, C3-7 cycloalkoxy, C1-6 linear haloalkyl, C3-7 branched haloalkyl, C1-6 linear haloalkoxy, or heterocyclyl.